TG Therapeutics


TG Therapeutics And Samsung Biologics Expand Ublituximab Manufacturing

Commercial-stage biopharmaceutical company TG Therapeutics and Samsung Biologics are expanding a large-scale manufacturing contract for the former’s ublituximab, an investigational monoclonal antibody. TG …

MLV Comments On TG Therapeutics Following Discussions With Management

Before the market opened today, MLV analyst Arlinda Lee reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, which …

UPDATE: MLV Raises TG Therapeutics Price Target Following TG-1101 And TGR-1202 Data At ASH

In a research report released this morning, MLV analyst Arlinda Lee maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price target …

Why Wouldn’t Pharmacyclics Take TG Out? Roth Capital Comments

In a research report sent to investors, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a price …

Brean Capital Reiterates Buy On TG Therapeutics Following ASH Presentation

In a research report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price …

Roth Capital Reiterates Buy On TG Therapeutics Following TG-1101 Update

In a research report sent to investors yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a …

Brean Capital Reiterates Buy On TG Therapeutics Following TGR-1202 Interim Data Release

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, …

Roth Capital Maintains Buy On TG Therapeutics Following Initiation Of Phase I/Ib Combination Study

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $25 price …

Brean Capital Maintains Buy On TG Therapeutics Following 3Q14 Update

Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) with a $22 price target, following the company’s third-quarter financial results and …

TG Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note issued yesterday, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts